Senti Biosciences Reports Promising Phase 1 Trial Results

Senti Biosciences ( (SNTI) ) has shared an announcement.

On December 9, 2025, Senti Biosciences announced initial clinical data from a Phase 1 trial of SENTI-202, a novel cell therapy for relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML). The trial results showed promising efficacy and safety, with a 50% overall response rate and 42% complete remission rate. The therapy’s novel mechanism selectively targets cancer cells while sparing healthy cells, and the FDA granted it Regenerative Medicine Advanced Therapy designation, supporting its potential for rapid advancement into pivotal studies.

The most recent analyst rating on (SNTI) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Senti Biosciences stock, see the SNTI Stock Forecast page.

Spark’s Take on SNTI Stock

According to Spark, TipRanks’ AI Analyst, SNTI is a Neutral.

Senti Biosciences is currently facing significant financial challenges, with ongoing losses and high leverage being the most critical issues. While technical analysis suggests some positive momentum, the overall valuation is weak due to negative earnings. However, recent corporate events, such as promising trial data and strategic leadership changes, provide a positive outlook, offering potential upside if financial stability can be improved.

To see Spark’s full report on SNTI stock, click here.

More about Senti Biosciences

Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform. The company is engaged in creating innovative treatments for various hematologic and solid cancers.

Average Trading Volume: 174,825

Technical Sentiment Signal: Sell

Current Market Cap: $56M

For a thorough assessment of SNTI stock, go to TipRanks’ Stock Analysis page.